Evogene Ltd Ord (EVGN) Stock Price, Quote & News

Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through three segments: Agriculture, Human Health, and other Industrial Applications. The Agriculture segmen...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 8 931 1900

Fax: 972 8 946 6724

Website: www.evogene.com

Address:

13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel

Microdreams Jan. 29 at 2:38 PM

$EVGN A matter of time https://www.reuters.com/legal/litigation/drugmakers-turn-ai-speed-trials-regulatory-submissions-2026-01-26/

0 · Reply

peepthestamp Jan. 25 at 7:37 PM

$BNBX $EVGN $HCWB -Aging well 🫡

1 · Reply

Milos89 Jan. 25 at 1:56 AM

$EVGN 1,5-2$ pricetarget

0 · Reply

Milos89 Jan. 25 at 1:56 AM

$EVGN

0 · Reply

Azlvr Jan. 23 at 9:15 PM

$EVGN Review Alejos here.🙃 https://www.trustpilot.com/review/www.jccapitalconsultants.com

0 · Reply

Microdreams Jan. 20 at 11:31 PM

$EVGN $EVGN The AI Drug Discovery market is coming to life faster than NVDA can make a new chip. Proxima raises 80m probably at 800m valuation and this is after Insilico Medicine ipo at 1.7b and trades at 3b one month later https://www.businesswire.com/news/home/20260113074220/en/Proxima-Raises-%2480-Million-Led-by-DCVC-to-Power-the-Next-Generation-of-Proximity-Based-Medicines Evogene should be 4-7 per shares once market gets a hold of their 20-30 PhDs and partners coming.

0 · Reply

opgntozero Jan. 16 at 2:35 PM

$EVGN not good! Evogene Ltd. Announces CFO Changes https://www.marketscreener.com/news/evogene-ltd-announces-cfo-changes-ce7e58deda8cf624

1 · Reply

Microdreams Jan. 15 at 8:56 PM

$EVGN $EVGN Trades at 10m with 16m cash They have an AI drug discovery engine with over 40 billion molecules and 3 partners. $GOOG has been behind them in a limited way for 1 1/4 years improving the value of the the engine called AI Chempass. Last month, Insilico Medicine , a MIT based company , went IPO at 1.7b valuation. Today it’s 3-3.5 billion up 100% in a month. Evogene , has been at it 3-4 years vs 10 years at Insilico but their molecule base comes from their previous parent company compugen. With the proper news or wins Evogene could be 1-3 billion in the future but with the right news and awareness it can be 100m overnight. Long and strong

1 · Reply

BillionerOfKing Jan. 15 at 8:50 PM

$EVGN Current Stock Price: $1.06

0 · Reply

SuperGreenToday Jan. 10 at 5:28 AM

$EVGN

0 · Reply

Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders

Dec 30, 2025, 7:00 AM EST - 5 weeks ago

Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development

Dec 11, 2025, 6:22 PM EST - 7 weeks ago

EverGen Infrastructure Corp. (EVGN:CA) Shareholder/Analyst Call Prepared Remarks Transcript

Nov 21, 2025, 12:13 PM EST - 2 months ago

EverGen Infrastructure Corp. (EVGN:CA) Q3 2025 Earnings Call Transcript

Nov 20, 2025, 12:13 PM EST - 2 months ago

Evogene Ltd. (EVGN) Q3 2025 Earnings Call Transcript

Nov 20, 2025, 7:00 AM EST - 2 months ago

Evogene Reports Third Quarter 2025 Financial Results

Nov 11, 2025, 7:00 AM EST - 3 months ago

Casterra and Fantini Partner to Advance Agricultural Mechanization for Scalable Commercial Castor Farming

Nov 6, 2025, 9:00 AM EST - 3 months ago

Evogene Schedules Third Quarter 2025 Financial Results Release

Aug 28, 2025, 7:00 AM EDT - 5 months ago

Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York

Aug 19, 2025, 1:31 PM EDT - 6 months ago

Evogene Ltd. (EVGN) Q2 2025 Earnings Call Transcript

Aug 19, 2025, 7:00 AM EDT - 6 months ago

Evogene Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 7:00 AM EDT - 6 months ago

Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases

Jul 29, 2025, 7:00 AM EDT - 6 months ago

Evogene Schedules Second Quarter 2025 Financial Results Release

Jul 8, 2025, 7:00 AM EDT - 7 months ago

Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL

ICL

Jun 10, 2025, 7:00 AM EDT - 8 months ago

Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud

May 21, 2025, 2:08 PM EDT - 9 months ago

Evogene Ltd. (EVGN) Q1 2025 Earnings Call Transcript

May 21, 2025, 7:00 AM EDT - 9 months ago

Evogene Reports First Quarter 2025 Financial Results

May 8, 2025, 7:00 AM EDT - 9 months ago

Evogene Schedules First Quarter 2025 Financial Results Release

Apr 21, 2025, 7:00 AM EDT - 10 months ago

ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio

Mar 6, 2025, 12:48 PM EST - 11 months ago

Evogene Ltd. (EVGN) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 7:15 AM EST - 11 months ago

Evogene Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 6, 2025, 7:00 AM EST - 11 months ago

Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025

Feb 20, 2025, 7:00 AM EST - 1 year ago

Evogene Schedules Fourth Quarter 2024 Financial Results Release

Feb 13, 2025, 8:00 AM EST - 1 year ago

AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease

Nov 21, 2024, 1:46 PM EST - 1 year ago

Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript

Nov 21, 2024, 7:30 AM EST - 1 year ago

Evogene Reports Third Quarter 2024 Financial Results

Nov 19, 2024, 7:00 AM EST - 1 year ago

Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results

Nov 12, 2024, 7:00 AM EST - 1 year ago

Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials

Nov 7, 2024, 7:00 AM EST - 1 year ago

Evogene Schedules Third Quarter 2024 Financial Results Release

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Casterra Announces a Key Milestone in its Operational Expansion Plan in Africa, with Completion of First Shipment of Castor Seeds Grown and Processed in Kenya

Oct 8, 2024, 7:00 AM EDT - 1 year ago

Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Lavie Bio Receives Grant from Israel Innovation Authority to Advance the Development of 'MicroFermentor', a Unique Technology that Can Change the Economics of Ag-Biologicals

Aug 23, 2024, 8:55 AM EDT - 1 year ago

Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement

Aug 22, 2024, 5:42 PM EDT - 1 year ago

Evogene Ltd. (EVGN) Q2 2024 Earnings Call Transcript

Aug 22, 2024, 7:00 AM EDT - 1 year ago

Evogene Reports Second Quarter 2024 Financial Results

Aug 12, 2024, 7:11 AM EDT - 1 year ago

Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Evogene Schedules Second Quarter 2024 Financial Results Release

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Casterra Announces the Completion of a Successful Castor Seed Growing and Harvesting Season in Brazil

Jul 23, 2024, 8:48 AM EDT - 1 year ago

Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split

Jul 17, 2024, 8:00 AM EDT - 1 year ago

ICL and Lavie Bio Leverage Artificial Intelligence to Make Significant Advancement in Development of Yield Increasing Bio-Stimulants

ICL

Jul 2, 2024, 7:00 AM EDT - 1 year ago

Lavie Bio Announces Commercial Expansion of Yalos™ to Winter Wheat

Jun 25, 2024, 7:00 AM EDT - 1 year ago

Casterra Announces an Additional Purchase Order to Supply Castor Seeds to a New African Country

May 23, 2024, 4:57 PM EDT - 1 year ago

Evogene Ltd. (EVGN) Q1 2024 Earnings Call Transcript

$Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma$

May 23, 2024, 11:00 AM EDT - 1 year ago

Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma

May 23, 2024, 7:00 AM EDT - 1 year ago

Evogene Reports First Quarter 2024 Financial Results

May 21, 2024, 7:03 AM EDT - 1 year ago

Casterra Announces Additional Agreements with Seed Producers to Meet Existing & Growing Demand for its Elite Castor Seeds

May 9, 2024, 7:00 AM EDT - 1 year ago

Evogene Schedules First Quarter 2024 Financial Results Release

Apr 16, 2024, 7:00 AM EDT - 1 year ago

Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Biomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual Meeting

Microdreams Jan. 29 at 2:38 PM

$EVGN A matter of time https://www.reuters.com/legal/litigation/drugmakers-turn-ai-speed-trials-regulatory-submissions-2026-01-26/

0 · Reply

peepthestamp Jan. 25 at 7:37 PM

$BNBX $EVGN $HCWB -Aging well 🫡

1 · Reply

Milos89 Jan. 25 at 1:56 AM

$EVGN 1,5-2$ pricetarget

0 · Reply

Milos89 Jan. 25 at 1:56 AM

$EVGN

0 · Reply

Azlvr Jan. 23 at 9:15 PM

$EVGN Review Alejos here.🙃 https://www.trustpilot.com/review/www.jccapitalconsultants.com

0 · Reply

Microdreams Jan. 20 at 11:31 PM

0 · Reply

opgntozero Jan. 16 at 2:35 PM

$EVGN not good! Evogene Ltd. Announces CFO Changes https://www.marketscreener.com/news/evogene-ltd-announces-cfo-changes-ce7e58deda8cf624

1 · Reply

Microdreams Jan. 15 at 8:56 PM

1 · Reply

BillionerOfKing Jan. 15 at 8:50 PM

$EVGN Current Stock Price: $1.06

0 · Reply

SuperGreenToday Jan. 10 at 5:28 AM

$EVGN

0 · Reply

omenkes Jan. 8 at 2:33 PM

$EVGN A story about Lavie Bio whose activity was sold to ICL in July of 2025. It starts with a 2024 presentation of Lavie Bio: https://evogene.com/wp-content/uploads/2024/12/Lavie_Bio_new_deck_Dec_2024_FINAL.pdf continues with the sale of the activity of lavie bio: https://evogene.com/newsroom/press-releases/icl-to-acquire-the-activity-of-evogenes-subsidiary-lavie-bio/ please see that in the sale programs with Bayer and Syngenta were not sold. they remain with Corteva (who stopped its program with Lavie Bio at the end of 2024 as a strategic focus on the chemical side of crop protection and away from the bio side) - 28% and Evogene - 72%. According to the Lavie Bio presentation, Bayer is working on LAV321 advancement and according to https://www.bioagworlddigest.com/2024/11/lavie-bio-advances-its-bio-fungicide-lav321-targeting-downy-mildew-to-pre-commercial-stage-following-successful-2024-field-trial-results/ Bayer should have applied for registration in 2025. Europe market size for grapes is $350M + $150M later in other fruits. sales estimate > $100M. other markets taken into account. Syngenta program not discussed here and corteva's termination of lav311 & lav312 https://www.nasdaq.com/articles/evogene-says-corteva-terminates-licensing-agreement-lavie-bio-subsidiary not sure of nature of other programs with corteva.

0 · Reply

omenkes Jan. 3 at 6:24 PM

$EVGN A story about agplenus (Chempass AI for agriculture) and Bayer crop science with a bit of a timeline (hope somebody cares): 1. 2020 - https://evogene.com/press_release/agplenus-announces-reaching-a-lead-stage-in-its-novel-mode-of-action-herbicide-program/ - agplenus reaches "lead" with aph-1 targeted herbicide. there is a clip to the effect on resistant weeds of the herbicide. 1 a. 2021 - https://agplenus.com/agplenus-announces-positive-results-for-a-herbicide-resistance-trait-to-its-leading-herbicide-product-candidate/ - resistence traits can be added to plants like soybeans. 2. 2/2024 - https://www.greentreechem.com/news/bayer-and-agplenus-jointly-develop-new-targete-75381067.html - apth-1 is the old aph-1 from 2020. Bayer cropkey will validate and optimize candidates. 3. 7/2024 - https://www.thefutureofclean.blog/post/ai-in-agriculture - cropkey is unveilled. herbicide molecule already identified. article talks about first herbicide in 30 years with new moa. 3. 2025 - agplenus current pipeline https://agplenus.com/products/ please see that the Bayer collaboration herbicide is in confidential stage. agplenus calls the moa aph-1. 4. 2025 - https://www.bayer.com/media/blockbuster-icafolin-bayer-reicht-zulassungsantraege-fuer-neuartiges-herbizid-in-vier-wichtigen-maerkten-ein/ - the agplenus aph-1 sounds very similar to what this new herbicide will do. Just a random thought.

2 · Reply

omenkes Jan. 2 at 9:03 PM

$EVGN https://www.prnewswire.com/news-releases/biomica-presents-positive-clinical-data-update-from-ongoing-phase-1-trial-of-microbiome-based-therapeutic-bmc128-for-refractory-rcc-nsclc--melanoma-302154259.html This was an update from 2024 on the Biomica 2024 ongoing phase 1. the phase 1 should be finished and presented in the first half of the year. 20% of Biomica belong to a chinese healthcare venture fund called shc. they bought it for $10M while Evogene put in another $10M. the fact that the phase 1 took as long as it did might actually indicate good results (decent survival). beyond 128, Biomica has two clinical trial ready candidates. in Evogene there are a few more parts that are chemical based (Biomica = biotics = biologicals). those chemical parts are chempass AI and agplenus (which is the ag application of the Chempass AI).

0 · Reply

peepthestamp Jan. 2 at 10:44 AM

$HCWB $BNBX $EVGN

0 · Reply

omenkes Jan. 1 at 10:21 PM

$EVGN https://www.fiercebiotech.com/biotech/enveda-harvests-another-150m-advance-nature-inspired-drugs here is another one that , this time, is still private.

0 · Reply

Microdreams Dec. 31 at 7:04 PM

$EVGN https://www.nasdaq.com/articles/insilico-medicine-debuts-hkex-first-ai-driven-biotech-under-chapter-805

1 · Reply

Microdreams Dec. 31 at 6:52 PM

$EVGN Evgn Astoundingly shares trade 1.00 or 9.1m mkt cap with 16m in cash and one of 2 subsidiaries worth at least 20m on a fire sale. The stock should be 3-4 per share without the biggest event to date for them Even more incredibly, an AI drug discovery company based out of MIT called Insilico Medicine went IPO at 1.7b and trades at 2.3b 2 days ago. They have a head start on AI chempass but we have a great AI machine with Google behind us that is certainly 1/40th the technology or 80-100m market cap When market wakes up it could fly to 5-7 January effect ?!

0 · Reply

DJTHollaAtMe Dec. 30 at 3:59 PM

$EVGN Really? Stupidly cheap. Someone should be buying this up at these levels. Ridiculous.

0 · Reply

ApexSignalMatrix Dec. 27 at 8:27 AM

$EVGN Expectations are resetting toward sustainable results, not one‑off wins. Margins must hold as the company navigates cost pressure. Any deterioration in traction could reset expectations abruptly. Execution quality becomes the defining catalyst from here.

0 · Reply

Xefna Dec. 24 at 11:54 AM

$EVGN Has the pipeline changed since 2023? This is able to soar on the smallest bit of news due to low float.

1 · Reply

DJTHollaAtMe Dec. 17 at 2:58 PM

$EVGN Market cap is SOOOO cheap especially given the sector they are breaking into! WOW!! Genetic engineering for agriculture is the future and EVGN will be a large participant.

0 · Reply

KAMIKAZ3TIGER Dec. 15 at 3:45 PM

$EVGN added again.

0 · Reply

Market Cap	5.42M
Revenue (ttm)	8.51M
Net Income (ttm)	-16.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-193.77%
Debt to Equity Ratio	0.00

Volume	36,400
Avg Vol	45,908
Day's Range	N/A - N/A
Shares Out	5.37M
Stochastic %K	45%
Beta	1.28
Analysts	Strong Buy
Price Target	$2.50